Ocuphire Pharma (NASDAQ:OCUP) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Free Report) in a research report released on Monday morning, Benzinga reports. The firm currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) […]

Related Keywords

George Magrath , Ocuphire Pharma , Richmond Brothers Inc , Vanguard Group Inc , Ocuphire Pharma Company Profile , Alliance Global Partners , Nasdaq , Kestra Private Wealth Services , Ocuphire Pharma Inc , Acadian Asset Management , Free Report , Get Free Report , Private Wealth Services , Asset Management , Empowered Funds , Phentolamine Ophthalmic Solution , Ocuphire Pharma Daily ,